| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial MR Gilbert, M Wang, KD Aldape, R Stupp, ME Hegi, KA Jaeckle, ... Journal of clinical oncology 31 (32), 4085-4091, 2013 | 1118 | 2013 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1065 | 2014 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The lancet oncology 18 (10), 1373-1385, 2017 | 1034 | 2017 |
| Current concepts and management of glioblastoma M Preusser, S De Ribaupierre, A Wöhrer, SC Erridge, M Hegi, M Weller, ... Annals of neurology 70 (1), 9-21, 2011 | 624 | 2011 |
| ESTRO-ACROP guideline “target delineation of glioblastomas” M Niyazi, M Brada, AJ Chalmers, SE Combs, SC Erridge, A Fiorentino, ... Radiotherapy and oncology 118 (1), 35-42, 2016 | 424 | 2016 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 395 | 2017 |
| Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer SC Erridge, Y Seppenwoolde, SH Muller, M van Herk, K De Jaeger, ... Radiotherapy and Oncology 66 (1), 75-85, 2003 | 381 | 2003 |
| Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma M Brada, S Stenning, R Gabe, LC Thompson, D Levy, R Rampling, ... Journal of clinical oncology 28 (30), 4601-4608, 2010 | 296 | 2010 |
| The accuracy of meningioma grading: a 10‐year retrospective audit J Willis, C Smith, JW Ironside, S Erridge, IR Whittle, D Everington Neuropathology and applied neurobiology 31 (2), 141-149, 2005 | 265 | 2005 |
| Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 … MJ van den Bent, CMS Tesileanu, W W, M Sanson, AA Brandes, ... Lancet Oncology 22 (6), 813-823, 2021 | 245 | 2021 |
| Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study D Cavers, B Hacking, SE Erridge, M Kendall, PG Morris, SA Murray Cmaj 184 (7), E373-E382, 2012 | 185 | 2012 |
| RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). MR Gilbert, M Wang, KD Aldape, R Stupp, M Hegi, KA Jaeckle, ... Journal of Clinical Oncology 29 (15_suppl), 2006-2006, 2011 | 160 | 2011 |
| Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG DT Blumenthal, T Gorlia, MR Gilbert, MM Kim, L Burt Nabors, WP Mason, ... Neuro-oncology 19 (8), 1119-1126, 2017 | 157 | 2017 |
| Radiotherapy for pituitary adenomas: long-term efficacy and toxicity SC Erridge, DS Conkey, D Stockton, MWJ Strachan, PFX Statham, ... Radiotherapy and Oncology 93 (3), 597-601, 2009 | 134 | 2009 |
| Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey Y Lievens, N Defourny, M Coffey, JM Borras, P Dunscombe, B Slotman, ... Radiotherapy and oncology 112 (2), 178-186, 2014 | 132 | 2014 |
| Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma TA Lawrie, D Gillespie, T Dowswell, J Evans, S Erridge, L Vale, ... Cochrane Database of Systematic Reviews, 2019 | 131 | 2019 |
| Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial C Hanna, KM Kurian, K Williams, C Watts, A Jackson, R Carruthers, ... Neuro-oncology 22 (12), 1840-1850, 2020 | 116 | 2020 |
| International comparisons of survival from lung cancer: pitfalls and warnings SC Erridge, H Møller, A Price, D Brewster Nature clinical practice Oncology 4 (10), 570-577, 2007 | 110 | 2007 |
| Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules SC Erridge, MN Gaze, A Price, CG Kelly, GR Kerr, A Cull, RH MacDougall, ... Clinical Oncology 17 (1), 61-67, 2005 | 108 | 2005 |
| ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma M Niyazi, N Andratschke, M Bendszus, AJ Chalmers, SC Erridge, ... Radiotherapy and Oncology 184, 109663, 2023 | 96 | 2023 |
